

**Incident and recurrent AUD diagnosis in patients with T2DM  
at longer follow-up time period  
(comparison between propensity-score matched cohorts)**

Follow-up	semaglutide cohort	non-GLP-1RA anti-diabetes medications cohort	HR (95% CI)
<b>Incident AUD (n=25,670/cohort)</b>			
1-year	0.32% (81)	0.52% (134)	0.56 (0.43–0.74)
2-year	0.58% (149)	0.90% (231)	0.59 (0.48–0.73)
3-year	0.90% (232)	1.19% (305)	0.72 (0.60–0.85)
<b>Recurrent CUD (n=653/cohort)</b>			
1-year	23.4% (153)	33.2% (217)	0.61 (0.50–0.75)
2-year	29.3% (191)	38.9% (294)	0.64 (0.53–0.77)
3-year	33.5% (219)	41.7% (272)	0.68 (0.57–0.81)

